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Abstract 
Introduction 
Substandard and falsified medications pose significant risks to global health. Nearly one in five 
antimalarials circulating in low- and middle-income countries are substandard or falsified. We assessed 
the health and economic impact of substandard and falsified antimalarials on children under five in 
Nigeria, where malaria is endemic and poor-quality medications are commonplace. 
 
Methods 
We developed a dynamic agent-based SAFARI (Substandard and Falsified Antimalarial Research Impact) 
model to capture the impact of antimalarial use in Nigeria. The model simulated children with 
background characteristics, malaria infections, patient care-seeking, disease progression, treatment 
outcomes, and incurred costs. Using scenario analyses, we simulated the impact of substandard and 
falsified medicines, antimalarial resistance, as well as possible interventions to improve the quality of 
treatment, reduce stock-outs, and educate caregivers about antimalarial quality.  
 
Results 
We estimated that poor quality antimalarials are responsible for 12,300 deaths annually and $892 
million ($890-$893 million) in costs in Nigeria. If antimalarial resistance develops, we simulated that 
current costs of malaria could increase by $839 million (11% increase, $837-$841 million). The northern 
regions of Nigeria have a greater burden as compared to the southern regions, with 9,700 deaths and 
$698 million ($697-$700 million) in total economic losses annually due to substandard and falsified 
antimalarials. Furthermore, our scenario analyses demonstrated that possible interventions—such as 
removing stock-outs in all facilities ($1.11 billion), having only ACTs available for treatment ($594 
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million), and 20% more patients seeking care ($469 million)—can save hundreds of millions in costs 
annually in Nigeria. 
 
Conclusions 
The results highlight the significant health and economic burden of poor quality antimalarials in Nigeria, 
and the impact of potential interventions to counter them. In order to reduce the burden of malaria and 
prevent antimalarials from developing resistance, policymakers and donors must understand the 
problem and implement interventions to reduce the impact of ineffective and harmful antimalarials. 
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Introduction 
 
Malaria is endemic in Nigeria where the entire country’s 191 million residents are at risk [1, 2]. 
Plasmodium falciparum causes an estimated 99.7% of deaths due to malaria with a disproportionate 
number of deaths in children under five [1, 3]. In 2017, Nigeria had an estimated 53.7 million cases of 
malaria across all ages, which accounted for 25% of all clinical episodes of malaria worldwide [1]. 
Furthermore, 19% of the global estimate of malaria deaths (81,600 deaths in 2017) occurred in Nigeria, 
making Nigeria the single most malaria-burdened country in the world [1, 4]. According to the Nigerian 
Ministry of Health, about 480 billion Naira ($2.3 billion 2017 USD) is lost annually to malaria in the form 
of treatment costs, prevention efforts, and loss of work time [5].  
 
Antimalarials are one of the most commonly found medications to be substandard or falsified in low- 
and middle-income countries (LMICs) [6]. The World Health Organization (WHO) defines substandard 
medicines as authorized medical products that fail to meet either quality standards, specifications, or 
both [7]. Falsified medicines are medical products that deliberately or fraudulently misrepresent their 
identity, composition or source [7]. As a result of poor manufacturing, inadequate supply chain 
management and storage conditions, or sales beyond expiration, poor quality medications can contain 
sub-therapeutic concentrations of stated ingredients, improper ingredients or no active pharmaceutical 
ingredients [8, 9]. 
 
According to a recent meta-analysis, 19.1% of all antimalarials tested in LMICs were substandard or 
falsified [6]. Previous studies have estimated that 33-64% of antimalarial medicines circulating in Nigeria 
were substandard or falsified [10, 11]. Poor quality antimalarial medications place significant health, 
social, and economic burden on individuals and communities. Avertable costs are incurred through 
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prolonged illness from malaria due to treatment failure. Substandard and falsified antimalarials can 
extend the length of hospitalization, contribute to antimalarial resistance, and even lead to death [7, 12, 
13]. In addition to health effects, poor quality antimalarials impose avoidable economic costs to 
patients, their families and the health system, through costs of medical care and productivity losses [14, 
15]. Substandard and falsified antimalarials also increase health inequities [16].  
 
Despite the large disease burden, no studies to date have examined the country-level impact of 
substandard and falsified antimalarials in Nigeria. This project estimates the health and economic 
impact of substandard and falsified antimalarials in Nigeria overall, and for the northern and southern 
regions. It also assesses the effects of potential interventions to inform policy decisions to improve the 
quality of treatment, reduce stock-outs, and educate caregivers about antimalarial quality. 
 
Materials and methods 
 
The SAFARI (Substandard and Falsified Antimalarial Research Impact) model is an agent based model 
used to estimate the health and economic impact of substandard and falsified antimalarials on children 
under five [17, 18]. The methods for the development of the SAFARI model are described in detail in 
another publication [17], with adaptations specific to Nigeria outlined here. The SAFARI model was built 
in Python to simulate population characteristics, malaria infection, patient care-seeking, disease 
progression, treatment outcomes, and associated costs of malaria for children under five years of age. 
The model simulates 25,000 children (agents) under five in Nigeria, with each agent possessing 
demographic characteristics, individual incidence, and individual care-seeking probabilities. The 
demographic characteristics – geographic region, rural/urban, wealth quintile, and level of maternal 
education – were applied to each child in the model, according to the distributions from the most recent 
(2015) Nigeria Malaria Indictor Survey (MIS) [5]. The rate of malaria transmission varies regionally in 
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Nigeria, with high transmission in the north and lower in the south. This was incorporated through each 
agent’s individual probability of getting sick with malaria, which reflects the prevalence of malaria by 
region. 
 
Fig 1. Flow diagram for the Nigeria SAFARI model depicting 5 days in a one-year care-seeking cycle 
 
 
Fig 1 depicts a flow diagram of the SAFARI model for Nigeria. The model simulates a one-year time 
horizon in five-day increments to match the reported average duration of an uncomplicated malaria 
case, accounting for care-seeking and average duration of symptoms [19]. All agents (simulated children 
under five) move through the disease and care-seeking simulations based on their individual background 
characteristics. Agents become infected and symptomatic based on estimates of under-five malaria 
incidence and cases in Nigeria [1, 20, 21]. We simulate treatment from one of six locations: public 
facilities, private facilities, pharmacies/chemists, drug stores/drug hawkers/general retailers, community 
health workers (CHWs), or self-treatment; or observe the progression of the disease without seeking 
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care. Antimalarial treatment available in each location is based on the market share of three options: 
artemisinin combination therapies (ACTs), chloroquine, or other treatments (sulfadoxine-pyrimethamine 
(SP), amodiaquine, quinine and others) [5]. Each care location could run out of stock of antimalarials 
based on ACTwatch national stock data [22], where non-severe cases remain symptomatic through the 
next period. Agents may progress to severe malaria and then face the probability of dying while 
receiving treatment for severe malaria when hospitalized, or dying without receiving treatment in the 
community [23]. To account for the increase in adverse outcomes caused by substandard or falsified 
antimalarials, it was assumed that patients who received poor quality antimalarials faced a 50% increase 
in the probability of developing severe malaria within the week of receiving the treatment, reflecting the 
impact of reduced efficacy of antimalarials with lower amounts of active pharmaceutical ingredients 
(API) [7]. 
 
A literature review was conducted across five electronic databases [PubMed, EconLit (EBSCOhost), 
Global Health, Embase, and SCOPUS] to identify model inputs specific to Nigeria. Grey literature was 
also searched to identify inputs from sources such as ACTwatch, the Global Burden of Disease study, 
Malaria Atlas Project (MAP), Nigeria MIS, World Malaria Report, World Development Indicators, and the 
Worldwide Antimalarial Resistance Network (WWARN) [2, 20, 22, 24-32]. The main demographic, 
epidemiological, and cost inputs are outlined in Table 1, with additional inputs and coefficients included 
in Supporting Information Files. In order to account for the natural variation in epidemiological and cost 
inputs, data ranges were utilized where available to assign distributions and simulated to vary 
probabilistically. Epidemiological rates were varied with beta distributions and cost inputs with gamma 
distributions. Costs in Nigerian Naira were converted to 2017 USD using Nigeria’s inflation rates and 
2017 exchange rates from the Central Bank of Nigeria [33].  
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Table 1. Key Input Data for the SAFARI Model in Nigeria 
 
 Model Inputs Input Range Source 
Demographic & 
Epidemiological Data  
<5 Population at Risk 32,379,000  [34] 
Malaria Incidence 0.8096  [20] 
Inpatient Severe Malaria Cases (per 100,000 
people per year) 44.8  Estimated based on: [23] 
Treatment Failure Progression to Severe 0.020 (0.005–0.05) [28] 
Inpatient Severe Case Fatality Rate 0.08  [23] 
Severe Case Fatality Rate in the Community 0.15  [23] 
Case Fatality Rate Without Receiving Treatment 0.6 (0.45 – 0.8) [24] 
Inpatient Severe Case Rate of Neurological 
Sequelae 0.0313 (0.028–0.035) Estimated based on: [29] 
Healthcare Seeking 
Behavior 
Care-Seeking Behavior (%) 
 [5]  
  Public Facilities 19.9% 
  Private Facilities 7.0% 
  Pharmacies/Chemists 39.1% 
  Drug Stores/Drug Hawkers/General Retailers 0.8% 
  CHWs 0.9% 
  Self/Neighbors 20.2% 
  No Treatment 12.3% 
Medication Stock by 
Facility 
Public Facilities 
 [5] 
    % Stock ACTs  48.5% 
    % Stock Chloroquine 25.1% 
    % Stock Other Treatments 25.4% 
Private Facilities 
    % Stock ACTs  48.1% 
    % Stock Chloroquine 22.8% 
    % Stock Other Treatments 29.1% 
Pharmacies/Chemists 
    % Stock ACTs  36.7% 
    % Stock Chloroquine 30.8% 
    % Stock Other Treatments 32.6% 
Drug Stores/Drug Hawkers/General Retailers 
    % Stock ACTs  53.8% 
    % Stock Chloroquine 7.7% 
    % Stock Other Treatments 38.5% 
CHWs 
    % Stock ACTs  54.5% 
    % Stock Chloroquine 0.0% 
    % Stock Other Treatments 45.5% 
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Self/Neighbors 
    % Stock ACTs  29.1% 
    % Stock Chloroquine 32.1% 
    % Stock Other  Treatments 38.8% 
Probability of stock-
out 
Proportion of facilities without stock of ACTs 
 Estimated based on: [22] 
    Public Facilities 12.7% 
    Private Facilities 25.5% 
    Pharmacies/Chemists 0.1% 
   Drug Store/Drug Hawkers/General Retailers 11.6% 
    CHWs 0% 
 Assumption 
    Self/Neighbors 0% 
Medication 
Effectiveness 
ACT Cure Rate 0.9643 (0.9599 – 0.9687) Estimated based on: [35], [36], [37] 
Chloroquine Cure Rate 0.5444 (0.4246 – 0.7194) Estimated based on: [38], [39] 
Other Treatment Cure Rate 0.7266 (0.6731 – 0.7801) Estimated based on: [38-45] 
No Treatment Cure Rate 0  Assumption 
Medication Costs by 
Facility 
Public Facilities 
Average Cost of ACTs $0.00 
 [22] Average Cost of Chloroquine $0.00 
Average Cost of Other Treatments $0.00 
Private Facilities 
Average Cost of ACTs $2.10 ($1.53 – $2.67) 
[22] Average Cost of Chloroquine $0.41 ($0 – $0.91) 
Average Cost of Other Treatments $1.40 ($0.61 – $2.19) 
Pharmacies/Chemists 
Average Cost of ACTs $3.25 ($2.69 – $3.81) 
[22] Average Cost of Chloroquine $0.51 ($0.01 – $1.01) 
Average Cost of Other Treatments $1.47 ($0.71 – $2.23) 
Drug Stores/Drug Hawkers/General Retailers 
Average Cost of ACTs $2.08 ($1.66 – $2.50) 
[22] Average Cost of Chloroquine $0.25 ($0 – $0.75) 
Average Cost of Other Treatments $1.47 ($0.71 – $2.23) 
CHWs 
Average Cost of ACTs $0.00  
[22] Average Cost of Quinine $0.00  
Average Cost of Other Treatments $0.00  
Self/Neighbors 
Average Cost of ACTs $0.00 
 Assumption 
Average Cost of Quinine $0.00 
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Average Cost of Other Treatments $0.00 
Non-Medication 
Costs 
Median Cost per Hospitalization $10.24 ($2.04 – $18.44) [31] 
Median Testing Costs $1.11 ($0.87 – 1.35) Estimated based on: [22] 
Average Transportation Costs $1.09  [30-32] 
Productivity Losses Per Sick Day $6.30  Estimated based on: [25] 
Productivity Losses per Death $52,554.65  Estimated based on: [25] 
Proportions of SF 
Medications 
ACTs 
  Not SF (API > 85%) 0.882  Estimated based on: [9, 10, 46-49] 
  Category 1: API = 75-85% 0.064  
Estimated based on: [9, 10, 
22, 46-51]   Category 2: API = 50-75% 0.027  
  Category 3: API < 50% 0.027  
Chloroquine 
  Not SF (API > 85%) -.494  Estimated based on: [48, 52-54] 
  Category 1: API = 75-85% 0.273  Estimated based on: [9, 22, 48-51]  
  Category 2: API = 50-75% 0.118  Estimated based on: [9, 22, 
48-51]   Category 3: API < 50% 0.116  
Other Treatments    
  Not SF (API > 85%) 0.479  Estimated based on: [48, 49, 52-54] 
  Category 1: API = 75-85% 0.281  Estimated based on: [9, 22, 48-51] 
  Category 2: API = 50-75% 0.121  Estimated based on: [9, 22, 48-50, 52, 54] 
  Category 3: API < 50% 0.119  Estimated based on: : [9, 22, 48-54] 
ACTs - Artemisinin-based combination therapy; API – Active pharmaceutical ingredient; CHWs – 
community health workers; SF – substandard and falsified 
 
 
The treatment outcome for each agent in the model was determined based on individual treatment 
adherence rates, treatment efficacy by medication, and the API concentration of the specific treatment 
the agent-child received [35-47, 50-55]. Treatment efficacy and prevalence of substandard and falsified 
medicines for each antimalarial treatment was estimated with data extracted from the Worldwide 
Antimalarial Resistance Network (WWARN) database and prevalence studies specific to Nigeria [35-45, 
48, 49, 52]. Each modeled antimalarial medication was assigned an API percentage category (>85%, 75-
85%, 50-75% and <50%) and given a corresponding treatment efficacy where lower APIs reduced the 
likelihood of successful treatment. Each agent in the model was assigned a rate of treatment adherence, 
which also affected treatment success.  
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The primary model outputs are estimates of the health impact, direct costs, and productivity losses 
attributable to substandard and falsified antimalarials for all children under five in Nigeria. The health 
impact is presented as the number of uncomplicated and severe cases, neurological sequelae, and 
deaths due to malaria. Economic outputs assessed direct costs for transportation, testing, medications, 
consultation and hospitalization costs as well as productivity losses. Consultation costs included the cost 
to the patient and facility of supplemental medicines or food, additional increased costs of private 
facility care, and the cost of health care services excluding medication and testing. Productivity losses 
included lost caretaker time caring for sick children and long-term productivity losses over a lifetime due 
to malaria-induced disability or premature death. Direct costs were further separated into amounts paid 
by patients and caretakers out-of-pocket versus those incurred by health facilities.  
 
We compared the baseline estimate to a scenario with no substandard and falsified antimalarials (i.e. 
assuming all medicines have an API > 85%) to assess the added expenses of poor quality medications. In 
addition, we present a scenario where Plasmodium falciparum developed resistance to artemisinin-
based antimalarials, where treatment efficacies for ACTs were lowered to be the same as those for 
other treatments, leading to increased treatment duration. We present the health and economic 
outputs separately for the northern and southern regions of Nigeria. In addition to the main simulations, 
seven other scenarios of potential interventions were examined. These scenarios were chosen to 
represent various supply chain, antimalarial treatment policies and caregiver education interventions. 
The scenarios included: having no medication stock-outs (1) across all sectors,(2) in public facilities, or 
(3) in private facilities; (4) replacing chloroquine and other treatments with ACTs such that only ACTs are 
available for treatment; (5) replacing all substandard or falsified ACTs with good quality ACTs; (6) 
encouraging 20% more patients to seek care for malaria treatment; and (7) encouraging perfect 
adherence to antimalarial medications.  
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Results 
 
Annually, we simulated approximately 24 million cases of malaria in children under five in Nigeria. Of 
simulated cases that progressed to severe, we estimated 147,000 hospitalizations, 8,200 cases of 
neurological sequalae, and 78,000 deaths. The total economic impact of malaria in Nigeria was 
estimated at $7.76 billion (7.73-7.80 billion) with $7.36 billion (95% of total economic impact, 7.33-7.40 
billion) in productivity losses, including $4.1 billion in lifetime productivity losses and $3.08 billion in 
short-term productivity losses. Direct costs of seeking medical treatment for malarial were 
approximately $401 million (5% of total economic impact, 400.4-401.4 million), which included $7.5 
million for testing costs, $9.5 million for transportation costs, $316 million for consultation costs, $59.3 
million for medication costs, and $8.97 million for hospitalization costs. Up to 33% of the direct costs of 
malaria treatment ($124 million) were paid out-of-pocket, whereas the health facility incurred the 
remainder of the costs ($247 million). The health and economic burden of malaria in Nigeria is 
summarized in Table 2. 
 
Table 2. Estimated Burden of Malaria, the Health and Economic Impact of Substandard and Falsified 
Antimalarials, and Effect of Antimicrobial Resistance of ACTs in Nigeria 
 
  
  
  
  
Burden of Malaria No Substandard or Falsified Antimalarials Antimicrobial Resistance 
Baseline 95% CI Potential Savings 
Percent 
Difference p-value† 
Additional 
Costs 
Percent 
Difference p-value† 
He
al
th
 Im
pa
ct
 Average Number of Cases 24,000,000 (23,995,800 – 24,002,700) +1,300 0% 0.596 -1,300 0% 0.579 
Average Number Hospitalized 147,000 (146,900 – 147,700) -33,300 -23% <0.001 +19,200 +13% <0.001 
Average Number with NS 8,200 (8,100 – 8,200) -500 -6% <0.001 +800 +10% <0.001 
Average Number of Deaths 78,000 (77,800 – 78,300) -12,300 -16% <0.001 +7,700 +10% <0.001 
Ec
on
om
ic 
Im
pa
ct
 Total Economic Impact $7,760,000,000 
(7,729,178,500 – 
7,800,795,900) -$892,000,000 -11% <0.001 +$839,000,000 +11% <0.001 
Direct Costs $401,000,000 (400,398,700 – 401,399,000) -$29,800,000 -7% <0.001 +$44,600,000 +11% <0.001 
      Facility Costs $267,000,000 (266,997,100 – 267,799,200) -$20,000,000 -7% <0.001 +$29,900,000 +11% <0.001 
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      Out-of-Pocket Costs $134,000,000 (133,206,400 – 133,795,100) -$9,800,000 -7% <0.001 +$14,800,000 +11% <0.001 
All Productivity Losses $7,360,000,000 (7,328,289,900 – 7,399,886,800) -$862,000,000 -12% <0.001 $794,000,000 +11% <0.001 
      Short-Term*  $3,080,000,000 (3,042,502,100 – 3,109,500,200) -$203,000,000 -1% <0.001 +$369,000,000 +12% <0.001 
      Lifetime  $4,100,000,000 (4,086,615,200 – 4,113,241,200) -$648,000,000 -16% <0.001 +$405,000,000 +10% <0.001 
ACT – Artemisinin-based combination therapies; CI – Confidence interval; NS – Neurological sequelae 
* Short-Term productivity losses included caregiver time during care seeking and hospital stay, and opportunity 
costs incurred by the community-health worker program. Lifetime productivity losses included losses due to 
premature death and disability. 
† Unpaired t-tests were used to estimate the statistical significance of outputs (p<0.05) compared to 
baseline.  
 
 
Substandard and falsified antimalarials contributed significantly to the malaria burden in Nigeria. 
Replacing poor quality antimalarials with good quality ones resulted in 33,300 fewer hospitalizations and 
12,300 fewer deaths annually in the country. The annual economic impact of substandard and falsified 
antimalarials in Nigeria was estimated at $892 million ($890-$893 million), around 11% of the total 
economic burden of malaria. This included $648 million ($647.9-649.1 million) in lifetime productivity 
losses and $203 million ($202-$205 million) in short-term productivity losses each year as a result of 
poor quality antimalarials. Substandard and falsified antimalarials accounted for $29.85 million ($29.82-
$29.87 million) in direct costs annually, including $9.8 million ($9.78-$9.81 million) in out-of-pocket 
costs to patients who sought care.  
 
If artemisinin resistance were to emerge reducing the effectiveness of ACTs to the level of other 
treatments, we estimated that Nigeria could face 19,200 more hospitalizations and 7,700 additional 
deaths in patients under five seeking treatment each year. In our simulation, antimalarial resistance 
increased costs to Nigeria by $839 million ($837-$841 million) annually, representing 11% of the 
economic burden of malaria. This included increases in lifetime productivity losses by $405 million 
($404.8-$406 million), short-term productivity losses by $369 million ($368-$371 million), and direct 
costs by $44.65 million ($44.63-$44.67 million). We estimated that antimalarial resistance could add 
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$29.89 million ($29.87-$29.91 million) to health facility costs and $14.76 million ($14.75-$14.78 million) 
in out-of-pocket costs to patients who seek treatment every year, resulting in an 11% increase in direct 
costs.  
 
Table 3. The Health and Economic Impact of Substandard and Falsified Antimalarials in Nigeria: Northern 
vs. Southern Regions 
 
No
rt
h  
  
  
  
  
Burden of Malaria No Substandard or Falsified Antimalarials Antimicrobial Resistance 
Baseline 95% CI Potential Impact 
Percent 
Difference p-value 
Additional 
Costs 
Percent 
Difference p-value 
He
al
th
 Im
pa
ct
 
Average Number of Cases 18,900,000 (18,905,600 – 18,912,500) +6,200 0% 0.013 -5,900 0% 0.017 
Average Number 
Hospitalized 116,000 (115,900 – 116,600) -26,300 -23% <0.001 +14,900 +13% <0.001 
Average Number of Deaths 61,000 (60,700 – 61,200) -9,700 -16% <0.001 +6,000 +10% <0.001 
Ec
on
om
ic 
Im
pa
ct
 Total Economic Impact $6,090,000,000 ($6,057,711,900 – $6,114,788,000) -$698,000,000 -11% <0.001 +$653,000,000 +11% <0.001 
      Facility Costs $209,000,000 ($208,768,500 – $209,401,200) -$15,600,000 -7% <0.001 +$23,100,000 +11% <0.001 
      All Productivity Losses $5,770,000,000 ($5,743,514,900 – $5,800,573,400) -$675,000,000 -12% <0.001 +$619,000,000 +11% <0.001 
      Out-of-Pocket Costs $105,000,000 ($104,899,200 – $105,352,800)  -$7,660,000 -7% <0.001 +$11,500,000 +11% <0.001 
So
ut
h 
  
  
  
  
Burden of Malaria No Substandard or Falsified Antimalarials Antimicrobial Resistance 
Baseline 95% CI Cost Savings Percent Difference p-value 
Additional 
Costs 
Percent 
Difference p-value 
He
al
th
 Im
pa
ct
 
Average Number of Cases 5,090,000 (5,088,000 – 5,092,400) -4,800 0% 0.003 +4,600 0% 0.004 
Average Number 
Hospitalized 31,000 (30,900 – 31,200) -6,900 -22% <0.001 +4,300 +14% <0.001 
Average Number of Deaths 17,100 (17,000 – 17,100) -2,700 -16% <0.001 +1,700 +10% <0.001 
Ec
on
om
ic 
Im
pa
ct
 Total Economic Impact $1,680,000,000 ($1,669,991,000 – $1,687,483,600) -$193,000,000 -12% <0.001 +$185,000,000 +11% <0.001 
      Facility Costs $58,300,000 ($58,218,600 – $58,408,100) -$4,480,000 -8% <0.001 +$6,740,000 +12% <0.001 
      All Productivity Losses $1,590,000,000 ($1,583,302,900 – $1,600,785,600) -$187,000,000 -12% <0.001 +$175,000,000 +11% <0.001 
      Out-of-Pocket Costs $28,400,000 ($28,315,100 – $28,444,300) -$2,140,000 -8% <0.001 +$3,250,000 +11% <0.001 
CI – Confidence interval 
 
The northern and southern regional breakdown of results is presented in Table 3. The economic burden 
of malaria was found to be much greater in the northern region of Nigeria at $6.09 billion ($6.06-$6.11 
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billion) as compared to $1.68 billion ($1.67-$1.69 billion) in the south. Much of the difference between 
north and south can be explained by transmission rates, with populations in the north at greater risk for 
malaria. Our model simulated 18.9 million malaria cases (79% of all cases) in Nigeria’s northern region, 
where 65% of all children under five in the country live. In the southern region, we estimated 5.09 
million cases (21% of all cases) of malaria. In the north, we estimated that 261,000 cases per year 
advance to severe malaria leading to 61,000 deaths, compared to 70,500 severe cases and 17,100 
deaths in the south.  
 
The burden of substandard and falsified medicines was especially large in northern Nigeria, where their 
removal from the north would save $698 million ($697-$700 million) annually in contrast to $193 million 
($193.1-$193.8 million) in the South. On the other hand, if antimalarial resistance were to emerge for 
ACTs, we estimated that total costs of malaria would increase by $653 million ($652-$655 million) in the 
northern region and $185 million ($185.0-$185.8 million) in the southern region of Nigeria. 
 
Fig 2. Total Economic Impact of Intervention Scenarios 
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Fig 2 presents the impact that various interventions could have including improving the quality of 
antimalarial medications in Nigeria. Eliminating all stock-outs provided the greatest cost-savings at $1.11 
billion ($1.10-$1.11 billion) annually. Removing all substandard and falsified antimalarials offered an 
estimated annual savings of $892 million ($890-$893 million). Due to frequent utilization of other 
treatments, improving only the quality of ACTs but not those of other treatments saved only $161 
million ($157-$164 million) in costs annually. When ACTs were the only treatment option available for 
malaria, replacing chloroquine and other treatments, we estimated $594 million ($591-$698 million) in 
annual savings. Increasing the number of individuals who seek care for malaria by 20% was estimated to 
result in $469 million ($465-$473 million) in cost savings. Perfect medication adherence to antimalarials 
demonstrated a smaller impact ($63 million; $59.6-$67.2 million). 
 
Discussion 
 
The results demonstrate the threat posed by substandard and falsified antimalarials and the importance 
of improving access to good quality malaria treatment in Nigeria. Substandard and falsified antimalarials 
were estimated to be responsible for $892 million in costs annually in Nigeria, and was attributable for 
6-23% of the health and economic burden of malaria. If artemisinin resistance were to develop, reducing 
the effectiveness of ACTs, we simulated that current economic costs could increase by 11% annually, 
including rises in direct costs by 11%. Therefore, improving the quality of antimalarials would make a 
meaningful impact in reducing the burden of malaria in Nigeria.  
 
We observed that substandard and falsified antimalarials affect many more children in the north (9,700 
deaths and $698 million in costs) compared to the south (2,700 deaths and $193 million in costs). This is 
in line with known regional disparities where northern Nigeria has fewer healthcare providers, weaker 
infrastructure, more porous supply chains and a larger malaria disease burden. Although the north 
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comprises a larger area and population, the south tends to have greater availability of financial 
resources and lower poverty rates, leading to disparities in access to malaria testing, medications, and 
education about proper treatments [56, 57]. Humanitarian crisis such as the Boko Haram insurgency in 
the norther region of Borno contribute to increased burden of malaria in endemic regions from the 
disruptions in the health system [34]. Our results suggest that poor quality antimalarials are further 
exacerbate inequities, which was also observed in Uganda [16]. Greater efforts are especially needed in 
the northern region to protect vulnerable populations and reduce health and economic inequities.  
 
Our results are comparable to previously reported estimates of the malaria disease burden. For 
example, our model estimated a total of 24 million malaria cases in Nigerian children under five, which is 
comparable to approximately 25.8 million under-five malaria cases based on the WHO estimate that 
45% of malaria cases in Nigeria (53.7 million) occur in children under five [7, 34]. Our model estimated a 
total of 78,000 deaths, which is in line with UNICEF estimations that 9.8% of all under-five deaths in 
Nigeria in 2017 were due to malaria, estimated at 69,990 (50,509-96,460) deaths [58]. Furthermore, our 
model estimate of the annual burden of malaria in Nigeria at $7.76 billion 2017 USD is comparable to 
the annual cost of malaria estimated in Nigeria at 2,231 billion 2011 Naira ($12 billion 2017 USD) as 
malaria cases and deaths have comparably lessened by 2017 (89% and 60% of 2011 estimates, 
respectively) [59].  
 
Despite efforts by the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC) 
to manage the supply chain and regulate medicine quality, substandard and falsified medicines continue 
to proliferate in the Nigerian market. A disorganized network of sellers and weak regulation make the 
pharmaceutical system in Nigeria particularly vulnerable to unethical and corrupt practices, such as 
extortion of bribes and diversion of donated medications [60, 61]. Small numbers of pharmaceutical 
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manufacturers in Nigeria are insufficient to meet the local demand, requiring medications to be 
imported from other countries. The majority of imported medications originate from countries such as 
China and India, where substandard and falsified medications have been identified [62, 63]. To reduce 
the total burden of substandard and falsified antimalarials, policymakers should strengthen regulatory 
capacity to license manufacturers, ensure good manufacturing practices and perform quality control of 
antimalarials. This could protect malaria medication from threats of falsification, poor manufacturing, 
expiration, and degradation. The hot and humid conditions in which medications are transported, 
stored, and sold in these locations often facilitate the degradation of medicines, which can result in 
substandard effectiveness [64]. In addition, medications frequently expire due to weak distribution 
systems, making them ineffective. Improving pharmaceutical governance, supply chain management 
and antimalarial surveillance are essential to close doors to substandard and falsified antimalarials from 
permeating the supply chain. NAFDAC and the Federal Ministry of Health must coordinate to play a 
larger role in ensuring quality of medicines by securing supply chains, regulation and inspection while 
improving access to high quality medicines.  
 
Increasing access and utilization of ACTs would have a significant health and economic impact in Nigeria. 
ACTs are recommended as the first-line treatment for malaria by the World Health Organization (WHO) 
[34], and Nigeria adopted this recommendation in 2005 [4, 65]. The use of ACTs for malaria treatment in 
Nigeria increased from 2% in 2008 to 18% in 2013 [2]. Using existing data in our model, we show that 
ACTs were used only 36.6% of the time across all care sectors, suggesting that the use of ACTs is far 
below the national target of 80% by 2010 as specified in the National Malaria Strategic Plan [2, 5]. 
Chloroquine and SP therapies are other commonly prescribed antimalarial medications in Nigeria [2]. If 
ACTs replaced chloroquine, SP and other antimalarial treatments, we simulate that there will be $594 
million in total savings and 7,900 fewer deaths among children under five. 
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Efforts to empower pharmacists at public and private facilities to better manage antimalarials and 
reduce stock-outs can prevent patients from purchasing medicines from unregulated markets. The 
Nigerian supply chain of antimalarials result in frequent public (12.7%) and private (25.5%) facility stock-
outs [22]. Malaria medicine stock-outs are common in these sectors due to unmet funding needs, lack of 
proper training of workers in medicine procurement, and inadequate storage,  transportation and 
distribution [64]. Prevalent stock-outs push many patients to seek treatment in informal sectors, often 
receiving antimalarials from drug hawkers, unregistered pharmacies, or open drug markets [61]. 
Chemists and drug hawkers are often not trained in pharmacy and cannot ensure the legitimacy or 
safety of medications. We simulated that removing public and private stock-outs of antimalarials 
resulted in $732 million and $416 million in annual savings in Nigeria, respectively. Reducing stock-outs 
of antimalarial medications would not only improve access to malaria treatment but also reduce the 
overall costs of malaria for patients and the government. 
 
Our analysis has a number of key limitations. First, availability of some data inputs were limited, which 
made it difficult to capture the large heterogeneity within Nigeria [66, 67]. Extensive literature searches 
were conducted and data analyses were carried out to utilize the best and most recent data available for 
model parameters. To account for some heterogeneity, demographic characteristics were assigned to 
each agent as well as individual-specific incidence and care-seeking rates based on an analysis of the 
Nigeria MIS data so that results could be examined separately for northern and southern regions. Data 
on the prevalence of substandard and falsified antimalarials by location were limited, where we had to 
apply the same rates to all facility types within the country. While our scenario analyses examined the 
impact of various interventions, we did not have data to model the costs of implementing each scenario. 
Further data should be gathered to inform implementation costs for regulation, quality control, and 
education to reduce the impact of substandard and falsified medicines. Despite these limitations, we 
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believe this analysis presents important estimates of the health and economic impact of substandard 
and falsified antimalarials in Nigeria to raise awareness of the problem. 
 
Our results inform the Federal Ministry of Health, NAFDAC, the malaria community and policymakers of 
the significant impact that substandard and falsified antimalarials have in Nigeria. We demonstrate not 
only the current health and economic impact, but also the benefits that potential interventions could 
have in reducing the burden. These results should be used to ensure that investments are made to not 
only guarantee medication safety but also increase access to high quality antimalarial treatment. 
Reducing substandard and falsified antimalarials in Nigeria would decrease the malaria burden and also 
safeguard existing malaria treatments to remain viable. The Federal government, in collaboration with 
implementation agencies, international organizations, and healthcare workers including pharmacists 
should set up efforts to alleviate barriers of access to ACTs, and strengthen antimalarial supply chains. 
Improving antimalarial quality is essential in ensuring that people can place their trust in medications 
and their healthcare system, and reducing avertable illnesses, deaths, and costs. 
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